Excelsior Sciences spoke with Anna Brown at leading pharma and biotech publication Endpoints News, who captured the excitement around our $95 million Series A and New York State grant. Her article highlights how our team is radically accelerating small-molecule drug discovery and development—all from our compact Park Avenue lab.
Anna focuses on the business implications for Excelsior Sciences’ smart bloccs platform, and our strategic priority of securing drug discovery and even manufacturing collaborations in 2026.
We’re delighted by how thoroughly Anna captured the platform’s full range of capabilities, and what this means for pharma, biotech – and beyond. For example, she notes that by designing molecules in ways machines can use and AI can harness, Excelsior Sciences is transforming the discovery of small molecules, including next-generation modalities like degraders, covalent modifiers, and dimerizers.
Quoting our co-founder and COO Jana Jensen, the article explains how this approach will transform not just drug discovery, but manufacturing and even entirely new applications in flavors, fragrances, materials, and agriculture.
